Editas Medicine (EDIT) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Editas Medicine (EDIT) has outperformed Ocugen (OCGN) over the past year, losing 32.2% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -94.9% for EDIT. Ocugen is the larger company by market cap ($260.6 million vs $253.1 million), about 1.0 times the size, while Editas Medicine is growing revenue faster (+25.4% vs +8.8%).
Editas Medicine converts more of its revenue into profit, with a net margin of -395.0% versus -1537.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | OCGN |
|---|---|---|
| Share price | $1.64 | $0.7679 |
| Market cap | $253.12M | $260.55M |
| 1-day change | -4.09% | +4.79% |
| YTD return | -20.00% | -43.12% |
| 1-year return | -32.23% | -33.80% |
| 5-year return | -94.93% | -88.09% |
| EPS (TTM) | $-0.54 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | $4.41M |
| Revenue growth (YoY) | +25.39% | +8.83% |
| Net income (latest FY) | $-160.06M | $-67.85M |
| Operating margin | -394.89% | -1425.70% |
| Net margin | -395.01% | -1537.41% |
| 52-week high | $3.94 | $2.73 |
| 52-week low | $1.63 | $0.691 |
| Distance from 52-week high | -58.38% | -71.82% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.95% | +1484.84% |
| Average volume | 2.63M | 7.34M |
| Shares outstanding | 154.34M | 339.31M |
| Employees | 87 | 116 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Editas Medicine is more profitable, keeping -395.0 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
- Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs +8.83%).
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
EDIT vs OCGN FAQ
Which is bigger, Editas Medicine or Ocugen?
Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $253.12M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or OCGN?
EDIT returned -32.23% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.